Kenvue: Trump-Era Volatility Presents A More Attractive Opportunity, But Headwinds RemainSeeking Alpha • 09/27/25
The CEO behind Tylenol thought he'd found a way to work with the Trump administration. Then everything went off the rails.WSJ • 09/27/25
Attorneys urge court overseeing Tylenol autism lawsuits to consider Trump administration's stanceReuters • 09/25/25
RFK Jr.'s team wanted to tout an autism therapy. But a meeting with Tylenol's maker convinced the U.S. health secretary to put the emphasis on acetaminophenWSJ • 09/25/25
How Trump is spreading unproven information about Tylenol, autism, and vaccinesFast Company • 09/23/25
Kenvue stock rallies off record low after Trump press conference on alleged Tylenol-autism linkMarket Watch • 09/23/25
Kenvue is bracing for an explosion of litigation over its popular pain reliever Tylenol after the Trump administration warned that the drug's active ingredient is a potential cause of autismWSJ • 09/23/25